Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 13, 2020

Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia

  • Rella Indah Karunia , Anita Purnamayanti ORCID logo EMAIL logo and Fransiscus O.H. Prasetyadi



Postpartum bleeding and pregnancy induced hypertension – including preeclampsia – remain to be a great cause of maternal mortality. The use of aspirin for preventing preeclampsia has been practiced recently by fetomaternal specialists in Indonesia. This study aimed to analyze the impact of education using an aspirin booklet provided by pharmacists on knowledge and adherence in taking aspirin among pregnant women with high risk for preeclampsia.


This was one group of pretest-posttest study. We enrolled all pregnant women with high risk for preeclampsia screened at 11+0–13+6 weeks’ gestation at Fetomaternal Clinic, Dr. Ramelan Naval Hospital, Surabaya. All subjects prescribed with low-dose aspirin (100 mg) for preeclampsia prevention received oral and written education using the aspirin booklet and had been followed up for 2 months. Knowledge about aspirin for preeclampsia prevention was measured by a validated questionnaire developed for this study. Adherence to aspirin was measured by pill count method.


A total of 12 pregnant women with high risk for preeclampsia were included during the study period. This study showed a statistically significant difference on knowledge of preeclampsia prevention before and after receiving oral and written education using aspirin booklet (p-value = 0.020), as well as aspirin adherence (p-value = 0.011).


The use of oral education and written aspirin booklet provided by pharmacists had impact on knowledge of preeclampsia prevention and adherence in taking aspirin among pregnant women with high risk for preeclampsia. We recommend to conduct randomized control study of adequate number of subjects.


We acknowledge the Director of Dr. Ramelan Naval Teaching Hospital for supporting the current research and all pregnant women participating during the study period.

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ institutional review board.


[1] American College of Obstetric and Gynecology. ACOG Guideline on Hypertension in pregnancy. Washington, 2013.Search in Google Scholar

[2] Preeclampsia Foundation. Preeclampsia and Maternal Mortality: a Global Burden. Melbourne, 2013.Search in Google Scholar

[3] FMF. Education The 11–13 weeks scan. In: London, UK, 2017.Search in Google Scholar

[4] FMF. Assessment of risk for preeclampsia. In: London, UK, 2017.Search in Google Scholar

[5] Sweetman SC. Martindale the complete drug reference, 36th ed. London: Pharmaceutical Press, 2009:20–1.Search in Google Scholar

[6] Wright D, Poon L, Rolnik D, Syngelaki A, Delgado J, Vojtassakova D, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol 2017;217:685.e1–5.10.1016/j.ajog.2017.08.110Search in Google Scholar

[7] Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol 2017;8:261.10.3389/fimmu.2017.00261Search in Google Scholar

[8] Roberge S, Giguere Y, Villa P, Nicolaide K, Vainio M, Forest J. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis: editorial comment. Obstet Gynecol Surv 2012;67:760–2.10.1097/01.ogx.0000425641.72994.b5Search in Google Scholar

[9] Wright D, Syngelaki A, Akolekar R, Poon L, Nicolaides K. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213:62.e1–10.10.1016/j.ajog.2015.02.018Search in Google Scholar

[10] English F, Kenny L, McCarthy F. Risk factors and effective management of preeclampsia. Integr Blood Press Control 2015;8:7–12.10.2147/IBPC.S50641Search in Google Scholar

[11] Paikin JS, Eikelboom JW. Aspirin. Circulation 2012;125:439–43.10.1161/CIRCULATIONAHA.111.046243Search in Google Scholar

[12] NICE. Medicines Adherence: involving patiens in decisions about prescribed medicines and supporting adherence. Clin Guidel 76. 2009;1-21.Search in Google Scholar

[13] Notoatmodjo S. Promosi Kesehatan dan Perilaku Kesehatan. Jakarta: Rineka Cipta, 2012.Search in Google Scholar

[14] O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon L. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Am J Obstet Gynecol 2016;215:87.e1–17.10.1016/j.ajog.2015.08.034Search in Google Scholar

[15] Morikawa M, Yamada T, Yamada T, Sato S, Cho K, Minakami H. Effects of nulliparity, maternal age, and pre-pregnancy body mass index on the development of gestational hypertension and preeclampsia. Pregnancy Hypertens 2013;1:75–80.10.14390/jsshp.1.75Search in Google Scholar

[16] Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides K. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obs Gynecol 2013;42:634–43.10.1097/OGX.0000000000000018Search in Google Scholar

[17] WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–63.10.1016/S0140-6736(03)15268-3Search in Google Scholar

[18] Shao Y, Qiu J, Huang H, Mao B, Dai W, He X, et al. Pre-pregnancy BMI, gestational weight gain and risk of preeclampsia: a birth cohort study in Lanzhou, China. BMC Pregnancy Childbirth 2017;17:400.10.1186/s12884-017-1567-2Search in Google Scholar PubMed PubMed Central

[19] Shen M, Smith G, Rodger M, White R, Walker M, Wen S. Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One 2017;12:1–13.10.1371/journal.pone.0175914Search in Google Scholar PubMed PubMed Central

[20] Boyd H, Hassaan T, Jan W, Mads M. Associations of personal and family preeclampsia history with the risk of early-, intermediate-, and late-onset preeclampsia. Am J Epidemiol 2013;178:1611–9.10.1093/aje/kwt189Search in Google Scholar PubMed

[21] Poon LC, Kametas NA, Pandeva I, Valencia C, Nicolaides KH. Mean arterial pressure at 11 to13 weeks in the prediction of preeclampsia. Hypertension 2008;51:1027–33.10.1161/HYPERTENSIONAHA.107.104646Search in Google Scholar PubMed

[22] Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 to 13 weeks in the prediction of pre-eclampsia. Ultrasound Obs Gynecol 2007;30:742–9.10.1002/uog.5157Search in Google Scholar PubMed

[23] Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8–15.10.1159/000341264Search in Google Scholar PubMed

[24] Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecolgy Int 2014;2014:297397.10.1155/2014/297397Search in Google Scholar PubMed PubMed Central

[25] Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D. Oocyte Donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. Am J Obstet Gynecol 2016;214:328–39.10.1016/j.ajog.2015.11.020Search in Google Scholar PubMed

[26] Rolnik DL, Wright D, Poon LC, Syngelaki A, O’Gorman N, de Paco Matallana C, et al. ASPRE trial: performance of screening for preterm. Ultrasound Obs Gynecol 2017;50:492–5.10.1002/uog.18816Search in Google Scholar PubMed

[27] Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–14.10.1097/AOG.0b013e3181e9322aSearch in Google Scholar PubMed

[28] Chen WC, Lin KH, Huang YT, Tsai TJ, Sun WC, Chuah SK, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther 2017;45:1542–50.10.1111/apt.14079Search in Google Scholar PubMed

[29] Atallah A, Lecarpentier E, Goffinet F. Aspirin for prevention of preeclampsia. Drugs 2017;77:1819–31.10.1007/s40265-017-0823-0Search in Google Scholar PubMed PubMed Central

[30] Perneby C, Vahter M, Akesson A, Bremme K, Hjemdahl P. Thromboxane metabolite excretion during pregnancy – influence of preeclampsia and aspirin treatment. Thromb Res 2011;127:605–6.10.1016/j.thromres.2011.01.005Search in Google Scholar PubMed

[31] Abheiden C, Reuler A, Fuijkschot W, Vries J, Thijs A, Boer M. Aspirin adherence during high-risk pregnancies, a questionnaire study. Pregnancy Hypertens 2016;6:350–5.10.1016/j.preghy.2016.08.232Search in Google Scholar PubMed

[32] Adawiyani R. Pengaruh Pemberian Booklet Anemia Terhadap Pengetahuan dan Kepatuhan Minum Tablet Tambah Darah dan Kadar Hemoglobin Ibu Hamil. Universitas Surabaya, 2013.Search in Google Scholar

[33] Revida R. Pengetahuan Gizi dan Keamanan Pangan Jajanan Serta Kebiasaan Jajan Siswa Sekolah Dasar di Depok dan Sukabumi. Institut Pertanian Bogor, 2011.Search in Google Scholar

Received: 2019-10-11
Accepted: 2019-11-19
Published Online: 2020-01-13

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 2.6.2023 from
Scroll to top button